CSIMarket Company Name, Ticker, Customers, else..
 
Iridex Corp  (IRIX)
Other Ticker:  
 
 
Price: $1.9000 $-0.10 -5.000%
Day's High: $1.92 Week Perf: -6.4 %
Day's Low: $ 1.90 30 Day Perf: 0.53 %
Volume (M): 18 52 Wk High: $ 3.65
Volume (M$): $ 34 52 Wk Avg: $2.50
Open: $1.92 52 Wk Low: $1.63



 Market Capitalization (Millions $) 31
 Shares Outstanding (Millions) 16
 Employees -
 Revenues (TTM) (Millions $) 53
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0

Iridex Corp
Iridex Corp is a medical device company that specializes in developing, manufacturing, and marketing laser-based medical solutions for ophthalmology and other medical specialties. The company's products primarily focus on the treatment of eye diseases, including glaucoma and retinal diseases. Their laser systems are used by ophthalmologists worldwide for various procedures, such as the removal of abnormal tissues, coagulation of blood vessels, and treatment of retinal conditions. Iridex Corp aims to provide innovative and advanced solutions to enhance patient care and improve outcomes in the field of ophthalmology.


   Company Address: 1212 Terra Bella Avenue Mountain View 94043 CA
   Company Phone Number: 940-4700   Stock Exchange / Ticker: NASDAQ IRIX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Iridex Announces Convertible Note Financing: Bolstering Innovations in Laser-based Medical Systems

Published Mon, Aug 5 2024 12:01 PM UTC



Iridex Corporation, a global leader in providing laser-based medical systems and devices for the treatment of glaucoma and retinal diseases, has recently announced the execution of definitive agreements for a private placement financing. The financing involves a senior convertible promissory note with Lind Global Asset Management IX LLC, managed by The Lind Partner...
Product Service News

Revolutionizing Glaucoma Treatment: The First Enrolment in Iridex-Imperial College Study

Published Wed, Jan 24 2024 1:00 PM UTC

Iridex Corporation, situated in Mountain View, California, and Imperial College Healthcare NHS Trust in London, have announced their first patient enrolment in a collaborative medical research study. The study is set to explore the efficacy of treating glaucoma with MicroPulse Transscleral Laser Therapy (TLT) utilizing Iridex?s Cyclo G6 Laser and the MicroPulse P3 Delivery D...
Product Service News

Iridex's Next-Generation Lasers Illuminate a Bright Future for Treating Retina Disorders and Glaucoma.

Published Thu, Jan 11 2024 11:46 PM UTC

Celebrating 35 Years of Laser Innovation: Iridex Introduces Next-Generation Lasers for Retina Disorders and Glaucoma Treatment in the US MarketMOUNTAIN VIEW, Calif., Jan. 11, 2024 - Iridex Corporation, a renowned global leader in laser-based medical systems for eye diseases, has proudly announced the launch of its state-of-the-art Iridex 532 and Iridex 577 Lasers in the US ...
Iridex Corp

IRIX Triumphs Over Obstacles, Shines in Q3 Earnings Season

Iridex Corp, a leading medical equipment and supplies company, recently released its financial results for the third quarter of 2023 earnings season. While the company reported a net loss of $-0.11 per share, this is an improvement compared to the previous year's loss of $-0.17 per share. However, the revenue for the quarter declined significantly by -12.718% to $12.62 million, compared to $14.46 million in the same period a year ago.
This decline in revenue is in stark contrast to the overall trend in the Medical Equipment & Supplies sector, which saw a top-line gain during the same period. The company's management has not provided specific reasons for this decline, but some experts speculate that it may be due to slowing demand or other market factors.
Iridex Corp

Iridex Corp Shines Bright: Impressive Second Quarter 2023 Performance Leaves Competitors in Awe

Iridex Corp: Bleak Financial Performance Raises Concerns for Investors
Iridex Corp, a prominent player in the medical equipment and supplies sector, has recently witnessed a significant decline in its financial performance, leaving investors worried about the company's future prospects. The company's financial results for the May to July 01, 2023 interval reveal a troubling trend that raises serious concerns.
First and foremost, there has been a substantial increase in the company's loss per share, which now stands at $-0.17 per share compared to $-0.14 a year ago. Additionally, this marks a surge in losses from the previous quarter, where the loss per share was reported at $-0.13. Such a decline in profitability is a clear indication of the company's inability to effectively manage costs and generate sustainable revenues.






Iridex's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com